Astellas Pharma Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of Xtandi (enzalutamide) as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.
Men with locally advanced Prostate Cancer and who receive radiotherapy (RT) on top of their androgen deprivation therapy (ADT) using...
Background: Androgen deprivation therapy (ADT) is foundational in the management of advanced prostate cancer (PCa) and has benefitted from a recent explosion in scientific advances.
Androgen-deprivation therapy is offered to men with prostate cancer who have a rising prostate-specific antigen after curative therapy (PSA relapse) or who are considered not suitable for curative treatment...
Men with prostate cancer with positive margins, extraprostatic extension, positive lymph nodes, high prostate?specific antigen, or high Gleason Score are at high risk of recurrence following primary therapy. Androgen deprivation therapy...
In recent years cellular senescence has generated a lot of interest among researchers due to its involvement in normal aging process and also in common human diseases. During senescence, cells undergo alterations that include telomere...
This study sought to evaluate whether there were differences in survival between patients with prostate cancer – stratified into high risk and very high risk groups – who were treated with radiotherapy and androgen deprivation.
The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have high-risk prognostic factors will benefit from the addition of abiraterone acetate plus low-dose prednisone to androgen deprivation therapy (ADT; lutenizing hormone releasing hormone [LHRH] agonists or surgical castration).
Containing relevant Learning Zones, guidelines, trials and news.
The European Commission has granted marketing authorization in the European Union (EU) for Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi) from Bayer and Orion Corp, plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC)